Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 3.23%
- Poor long term growth as Net Sales has grown by an annual rate of -2.35% and Operating profit at 0.73% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
With ROE of 5.12%, it has a expensive valuation with a 1.72 Price to Book Value
3
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CNY 9,377 Million (Mid Cap)
34.00
NA
0.55%
1.88
5.12%
1.72
Revenue and Profits:
Net Sales:
2,669 Million
(Quarterly Results - Jun 2025)
Net Profit:
86 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-4.58%
0%
-4.58%
6 Months
-5.35%
0%
-5.35%
1 Year
0.69%
0%
0.69%
2 Years
-7.89%
0%
-7.89%
3 Years
-7.89%
0%
-7.89%
4 Years
-44.17%
0%
-44.17%
5 Years
-44.8%
0%
-44.8%
North China Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-2.35%
EBIT Growth (5y)
0.73%
EBIT to Interest (avg)
0.90
Debt to EBITDA (avg)
7.81
Net Debt to Equity (avg)
1.86
Sales to Capital Employed (avg)
0.60
Tax Ratio
31.01%
Dividend Payout Ratio
40.54%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
3.23%
ROE (avg)
1.59%
Valuation key factors
Factor
Value
P/E Ratio
34
Industry P/E
Price to Book Value
1.72
EV to EBIT
28.82
EV to EBITDA
12.26
EV to Capital Employed
1.25
EV to Sales
2.01
PEG Ratio
0.20
Dividend Yield
0.55%
ROCE (Latest)
4.33%
ROE (Latest)
5.12%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
2,668.70
2,547.50
4.76%
Operating Profit (PBDIT) excl Other Income
412.60
415.00
-0.58%
Interest
93.20
97.40
-4.31%
Exceptional Items
0.00
0.00
Consolidate Net Profit
85.70
76.60
11.88%
Operating Profit Margin (Excl OI)
66.20%
70.30%
-0.41%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 4.76% vs 11.86% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 11.88% vs 11.82% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
9,760.30
10,016.00
-2.55%
Operating Profit (PBDIT) excl Other Income
1,547.40
1,429.40
8.26%
Interest
468.60
511.90
-8.46%
Exceptional Items
-4.10
4.00
-202.50%
Consolidate Net Profit
215.00
49.40
335.22%
Operating Profit Margin (Excl OI)
68.90%
54.00%
1.49%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -2.55% vs -3.53% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 335.22% vs 107.28% in Dec 2023
About North China Pharmaceutical Co., Ltd. 
North China Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






